Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592858 | 0.89 | GABRA1 (1.00) | GABRA1 | |
| SCHEMBL20240983 | 0.89 | GABRA1 (1.00) | GABRA1 | |
| SCHEMBL2932611 | 0.88 | GABRA1 (0.80) | GABRA1GABRA5 | |
| SCHEMBL1776448 | 0.86 | GABRA1 (0.78) | GABRA1GABRA5 | |
| SCHEMBL2925823 | 0.86 | GABRA5 (1.00) | GABRA5 | |
| SCHEMBL20258931 | 0.86 | GABRA1 (0.93) | GABRA1 | |
| SCHEMBL2934882 | 0.85 | GABRA1 (0.69) | GABRA1GABRA5 | |
| SCHEMBL2934880 | 0.85 | GABRA5 (0.75) | GABRA5 | |
| SCHEMBL2927559 | 0.85 | GABRA5 (0.65) | GABRA5 | |
| SCHEMBL3210268 | 0.84 | GABRA5 (0.75) | GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229383-B1 | ISOXAZOLO-PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | claimed |
| EP-2229383-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | claimed |
| US-7618973-B2 | Isoxazolo-pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-17 | — | — | US | claimed |
| WO-2009071464-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | claimed |
| US-20090143407-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | claimed |
| EP-2229383-B1 | ISOXAZOLO-PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-7902201-B2 | Isoxazolo-pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100256154-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2229383-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100041886-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | BUETTELMANN BERND | 2010-02-18 | — | — | US | disclosed |
| US-7618973-B2 | Isoxazolo-pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-17 | — | — | US | disclosed |
| WO-2009071464-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143407-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143407-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA4 | GABRA1 6/4885GABRA5 1/4885 |
| US-20100256154-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | GABRA5, GRIK5, GABRA4 | GABRA1 6/4885GABRA5 1/4885 |
| US-20100041886-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA4 | GABRA1 6/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.